Journal article
Dermal elastolysis in the setting of combination immunotherapy
Journal of cutaneous pathology, Vol.46(9), pp.684-687
09/01/2019
DOI: 10.1111/cup.13492
PMID: 31074019
Abstract
Multiple cutaneous side effects have been reported with the use of immunotherapies including programmed cell death protein 1 inhibitors. We report 2 patients who presented with papillary dermal elastolysis presenting as multiple, skin-colored, wrinkled papules and atrophic macules following an inflammatory eruption in the setting of combination chemotherapy with nivolumab and cabiralizumab. These two cases highlight a novel finding, elastolysis in the setting of chemotherapy with nivolumab and cabiralizumab.
Details
- Title: Subtitle
- Dermal elastolysis in the setting of combination immunotherapy
- Creators
- Kirsten E. Dickinson - University of Iowa Hospitals and ClinicsLulit Price - University of Iowa Hospitals and ClinicsKarolyn A. Wanat - University of IowaBrian L. Swick - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Journal of cutaneous pathology, Vol.46(9), pp.684-687
- Publisher
- Wiley
- DOI
- 10.1111/cup.13492
- PMID
- 31074019
- ISSN
- 0303-6987
- eISSN
- 1600-0560
- Number of pages
- 4
- Language
- English
- Date published
- 09/01/2019
- Academic Unit
- Dermatology; Pathology
- Record Identifier
- 9984296311502771
Metrics
4 Record Views